Tag:
Ipsen
Latest Headlines
Latest Headlines
Osteoporosis drug developer Radius Health braves chilly IPO market
After burning through more than $122 million, the late-stage osteoporosis drug developer Radius Health is filing to go public in the hope of raising up to $86 million. Radius is betting that it can
Lonza trouble may trigger big writedown at Ipsen
Trouble flows downstream swiftly when a CMO finds itself in trouble. Just days after Lonza fired its CEO as it finds itself under the microscope after a warning letter from the FDA on one of its...
Ipsen hands back Parkinson's drug rights to Santhera
French drugmaker Ipsen ( $IPN ) has a game plan for developing new drugs, and Santhera's ($SANN) Parkinson's disease treatment fipamezole didn't make the cut. Switzerland-based Santhera said that it
UPDATED: Ipsen-backed Inspiration Biopharma leaving California for Boston area
Score one for the Boston-area biotech scene. With a newly appointed chief executive from Genzyme, Inspiration Biopharmaceuticals is relocating from Laguna Niguel, CA, to the biotech-rich Kendall
Ipsen plans new hires, $45M R&D expansion as it relocates U.S. HQ
Paris-based Ipsen is reorganizing its U.S. operations, shifting its American headquarters from California to New Jersey, hiring 100 employees and investing $45 million in an upgrade of its R&D
Radius Health collects $27.7M for PhIII osteoporosis program
Cambridge, MA-based Radius Health has drawn down a $27.7 million tranche from its $91 million financing round as it bores ahead with a pivotal Phase III program for its bone-building drug. In
Inspiration nabs $35M milestone on EMA hemophilia review
The EMA has accepted Inspiration Biopharmaceuticals' marketing app for its new treatment for hemophilia B, triggering a $35 million milestone payment from its European partner Ipsen. The French
UPDATED: ASCO roundup: Fresh progress of Merck, Pfizer cancer drugs
The burst of cancer drug news out of ASCO has spotlighted significant advances on a host of new drug programs, with Merck and Pfizer both benefiting from the limelight. (You can find fresh data on
Ipsen bows out of troubled toremifene pact with GTx
More than a year after GTx was hammered ($GTXI) by the FDA's rejection of toremifene and its demand for a new clinical trial of the bone loss drug, France's Ipsen has opted to bow out of its
Ipsen, Biomérieux sign companion diagnostics pact
Ipsen and bioMérieux have created a global collaboration in theranostics with a focus on hormone-dependent cancers. The partnership emphasizes the companies' expertise in the emerging field of
